Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 591 entries
Sorted by: Best Match Show Resources per page
Corrigendum.

Pediatric hematology and oncology

[No authors listed]
PMID: 28410059
Pediatr Hematol Oncol. 2017 Feb;34(1):51. doi: 10.1080/08880018.2017.1302271.

No abstract available.

Cite
Corrigendum. Pediatr Hematol Oncol. 2017;34(1):51doi: 10.1080/08880018.2017.1302271.
(2017). Corrigendum. Pediatric hematology and oncology, 34(1), 51. https://doi.org/10.1080/08880018.2017.1302271
"Corrigendum." Pediatric hematology and oncology vol. 34,1 (2017): 51. doi: https://doi.org/10.1080/08880018.2017.1302271
Corrigendum. Pediatr Hematol Oncol. 2017 Feb;34(1):51. doi: 10.1080/08880018.2017.1302271. PMID: 28410059.
Copy Download .nbib Format: NLM
Histopathology of nodular renal blastema.

The American journal of pediatric hematology/oncology

Sotelo-Avila C, deMello DE.
PMID: 4083406
Am J Pediatr Hematol Oncol. 1985;7(4):401.

No abstract available.

Cite
Sotelo-Avila C, deMello DE. Histopathology of nodular renal blastema. Am J Pediatr Hematol Oncol. 1985;7(4):401
Sotelo-Avila, C., & deMello, D. E. (1985). Histopathology of nodular renal blastema. The American journal of pediatric hematology/oncology, 7(4), 401.
Sotelo-Avila, C, and deMello, D E. "Histopathology of nodular renal blastema." The American journal of pediatric hematology/oncology vol. 7,4 (1985): 401.
Sotelo-Avila C, deMello DE. Histopathology of nodular renal blastema. Am J Pediatr Hematol Oncol. 1985;7(4):401. PMID: 4083406.
Copy Download .nbib Format: NLM
Ethical issues. How can we distinguish clinical research from innovative therapy?.

The American journal of pediatric hematology/oncology

Lantos J.
PMID: 8311175
Am J Pediatr Hematol Oncol. 1994 Feb;16(1):72-5.

The difference between research and innovative therapy is based on the goals rather than the risks or newness of the therapy. The threat to patients from research is not that an untested treatment may be hazardous. Instead, the danger...

Cite
Lantos J. Ethical issues. How can we distinguish clinical research from innovative therapy?. Am J Pediatr Hematol Oncol. 1994;16(1):72-5
Lantos, J. (1994). Ethical issues. How can we distinguish clinical research from innovative therapy?. The American journal of pediatric hematology/oncology, 16(1), 72-5.
Lantos, J. "Ethical issues. How can we distinguish clinical research from innovative therapy?." The American journal of pediatric hematology/oncology vol. 16,1 (1994): 72-5.
Lantos J. Ethical issues. How can we distinguish clinical research from innovative therapy?. Am J Pediatr Hematol Oncol. 1994 Feb;16(1):72-5. PMID: 8311175.
Copy Download .nbib Format: NLM
The role of whole-body MRI in pediatric oncology.

Journal of pediatric hematology/oncology

Atkin KL, Ditchfield MR.
PMID: 24072253
J Pediatr Hematol Oncol. 2014 Jul;36(5):342-52. doi: 10.1097/MPH.0000000000000031.

Pediatric whole-body (WB) magnetic resonance imaging (MRI) is an established technique that, with improved accessibility and advances in technology, is being used with increasing frequency for a wide variety of applications. The advantages of WB MRI (over other imaging...

Cite
Atkin KL, Ditchfield MR. The role of whole-body MRI in pediatric oncology. J Pediatr Hematol Oncol. 2014;36(5):342-52doi: 10.1097/MPH.0000000000000031.
Atkin, K. L., & Ditchfield, M. R. (2014). The role of whole-body MRI in pediatric oncology. Journal of pediatric hematology/oncology, 36(5), 342-52. https://doi.org/10.1097/MPH.0000000000000031
Atkin, Karen L, and Ditchfield, Michael R. "The role of whole-body MRI in pediatric oncology." Journal of pediatric hematology/oncology vol. 36,5 (2014): 342-52. doi: https://doi.org/10.1097/MPH.0000000000000031
Atkin KL, Ditchfield MR. The role of whole-body MRI in pediatric oncology. J Pediatr Hematol Oncol. 2014 Jul;36(5):342-52. doi: 10.1097/MPH.0000000000000031. PMID: 24072253.
Copy Download .nbib Format: NLM
Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients: Erratum.

Journal of pediatric hematology/oncology

[No authors listed]
PMID: 30346376
J Pediatr Hematol Oncol. 2018 Nov;40(8):631. doi: 10.1097/MPH.0000000000001319.

No abstract available.

Cite
Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients: Erratum. J Pediatr Hematol Oncol. 2018;40(8):631doi: 10.1097/MPH.0000000000001319.
(2018). Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients: Erratum. Journal of pediatric hematology/oncology, 40(8), 631. https://doi.org/10.1097/MPH.0000000000001319
"Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients: Erratum." Journal of pediatric hematology/oncology vol. 40,8 (2018): 631. doi: https://doi.org/10.1097/MPH.0000000000001319
Postchemotherapy Immunization Practices for Non-HSCT Pediatric Oncology Patients: Erratum. J Pediatr Hematol Oncol. 2018 Nov;40(8):631. doi: 10.1097/MPH.0000000000001319. PMID: 30346376.
Copy Download .nbib Format: NLM
Programmed Death Ligand 1 Expression in Classical Hodgkin Lymphoma in Pediatric Patients.

Journal of pediatric hematology/oncology

Aoki T, Kyushiki M, Kishimoto H, Yanagi M, Mori M, Arakawa Y, Hino M, Shimojo N, Koh K.
PMID: 29200165
J Pediatr Hematol Oncol. 2018 May;40(4):334-335. doi: 10.1097/MPH.0000000000001030.

No abstract available.

Cite
Aoki T, Kyushiki M, Kishimoto H, et al. Programmed Death Ligand 1 Expression in Classical Hodgkin Lymphoma in Pediatric Patients. J Pediatr Hematol Oncol. 2018;40(4):334-335doi: 10.1097/MPH.0000000000001030.
Aoki, T., Kyushiki, M., Kishimoto, H., Yanagi, M., Mori, M., Arakawa, Y., Hino, M., Shimojo, N., & Koh, K. (2018). Programmed Death Ligand 1 Expression in Classical Hodgkin Lymphoma in Pediatric Patients. Journal of pediatric hematology/oncology, 40(4), 334-335. https://doi.org/10.1097/MPH.0000000000001030
Aoki, Takahiro, et al. "Programmed Death Ligand 1 Expression in Classical Hodgkin Lymphoma in Pediatric Patients." Journal of pediatric hematology/oncology vol. 40,4 (2018): 334-335. doi: https://doi.org/10.1097/MPH.0000000000001030
Aoki T, Kyushiki M, Kishimoto H, Yanagi M, Mori M, Arakawa Y, Hino M, Shimojo N, Koh K. Programmed Death Ligand 1 Expression in Classical Hodgkin Lymphoma in Pediatric Patients. J Pediatr Hematol Oncol. 2018 May;40(4):334-335. doi: 10.1097/MPH.0000000000001030. PMID: 29200165.
Copy Download .nbib Format: NLM
Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants.

Journal of pediatric hematology/oncology

Andolina JR, Fries C, Boulware R, Vargas A, Fraint E, Barth M, Ambrusko S, Comito M, Monteleone P.
PMID: 33843815
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e264-e267. doi: 10.1097/MPH.0000000000002151.

BACKGROUND: Infant acute myeloid leukemia is a rare but aggressive form of leukemia.OBSERVATION: We report 2 children who presented with hyperleukocytosis, subsequently diagnosed with infant acute myeloid leukemia, and both developed isolated central nervous system relapse while on chemotherapy....

Cite
Andolina JR, Fries C, Boulware R, et al. Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants. J Pediatr Hematol Oncol. 2022;44(1):e264-e267doi: 10.1097/MPH.0000000000002151.
Andolina, J. R., Fries, C., Boulware, R., Vargas, A., Fraint, E., Barth, M., Ambrusko, S., Comito, M., & Monteleone, P. (2022). Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants. Journal of pediatric hematology/oncology, 44(1), e264-e267. https://doi.org/10.1097/MPH.0000000000002151
Andolina, Jeffrey R, et al. "Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants." Journal of pediatric hematology/oncology vol. 44,1 (2022): e264-e267. doi: https://doi.org/10.1097/MPH.0000000000002151
Andolina JR, Fries C, Boulware R, Vargas A, Fraint E, Barth M, Ambrusko S, Comito M, Monteleone P. Successful Bone Marrow Transplantation With Intensive Post-transplant Intrathecal Chemotherapy for CNS Relapsed AML in 2 Infants. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e264-e267. doi: 10.1097/MPH.0000000000002151. PMID: 33843815.
Copy Download .nbib Format: NLM
Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic.

Journal of pediatric hematology/oncology

Lo ZC, Sobota AE.
PMID: 33974583
J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e46-e50. doi: 10.1097/MPH.0000000000002192.

BACKGROUND: Children with sickle cell disease (SCD) are at high-risk of complications from influenza and should receive an influenza vaccination seasonally. Despite this recommendation, vaccination rates remain suboptimal. Boston Medical Center (BMC) previously achieved high influenza vaccination rates among...

Cite
Lo ZC, Sobota AE. Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic. J Pediatr Hematol Oncol. 2022;44(1):e46-e50doi: 10.1097/MPH.0000000000002192.
Lo, Z. C., & Sobota, A. E. (2022). Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic. Journal of pediatric hematology/oncology, 44(1), e46-e50. https://doi.org/10.1097/MPH.0000000000002192
Lo, Zachary C, and Sobota, Amy E. "Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic." Journal of pediatric hematology/oncology vol. 44,1 (2022): e46-e50. doi: https://doi.org/10.1097/MPH.0000000000002192
Lo ZC, Sobota AE. Maintenance of a High Influenza Vaccination Rate and Improvement in Health Outcomes in a Pediatric Sickle Cell Disease Clinic. J Pediatr Hematol Oncol. 2022 Jan 01;44(1):e46-e50. doi: 10.1097/MPH.0000000000002192. PMID: 33974583; PMCID: PMC8581069.
Copy Download .nbib Format: NLM
Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis.

Journal of pediatric hematology/oncology

Aldrian D, Neu N, Oberhuber G, Kropshofer G, Müller T, Vogel GF.
PMID: 33633025
J Pediatr Hematol Oncol. 2021 Feb 25; doi: 10.1097/MPH.0000000000002118. Epub 2021 Feb 25.

Malignant peritoneal mesothelioma (MPM) is an extremely rare entity with a poor prognosis. We report on a 16-year-old boy with ascites and abdominal distension. A computed tomography scan showed peritoneal thickening and a mass adjacent to the transverse colon....

Cite
Aldrian D, Neu N, Oberhuber G, et al. Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002118.
Aldrian, D., Neu, N., Oberhuber, G., Kropshofer, G., Müller, T., & Vogel, G. F. (2021). Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002118
Aldrian, Denise, et al. "Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002118
Aldrian D, Neu N, Oberhuber G, Kropshofer G, Müller T, Vogel GF. Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. J Pediatr Hematol Oncol. 2021 Feb 25; doi: 10.1097/MPH.0000000000002118. Epub 2021 Feb 25. PMID: 33633025.
Copy Download .nbib Format: NLM
Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia.

Journal of pediatric hematology/oncology

Borgstedt-Bendixen SE, Abrahamsson J, Ha SY, Koskenvuo M, Lausen B, Palle J, Zeller B, Hasle H, Løhmann DJA.
PMID: 34387627
J Pediatr Hematol Oncol. 2021 Aug 16; doi: 10.1097/MPH.0000000000002281. Epub 2021 Aug 16.

Acute myeloid leukemia (AML) accounts for 15% to 20% of childhood leukemias. Because of high-intensive therapy, up to 5% of patients suffer from treatment-related mortality (TRM). Abdominal complications are frequent, however, literature on this subject is sparse. We aimed...

Cite
Borgstedt-Bendixen SE, Abrahamsson J, Ha SY, et al. Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002281.
Borgstedt-Bendixen, S. E., Abrahamsson, J., Ha, S. Y., Koskenvuo, M., Lausen, B., Palle, J., Zeller, B., Hasle, H., & Løhmann, D. J. A. (2021). Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002281
Borgstedt-Bendixen, Sofie E, et al. "Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002281
Borgstedt-Bendixen SE, Abrahamsson J, Ha SY, Koskenvuo M, Lausen B, Palle J, Zeller B, Hasle H, Løhmann DJA. Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia. J Pediatr Hematol Oncol. 2021 Aug 16; doi: 10.1097/MPH.0000000000002281. Epub 2021 Aug 16. PMID: 34387627.
Copy Download .nbib Format: NLM
Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?.

Journal of pediatric hematology/oncology

Şen S, Özdemir HH, Karadaş N, Bal ZŞ, Göktepe ŞÖ, Ece D, Balkan C, Aydinok Y, Karapinar DY.
PMID: 34387629
J Pediatr Hematol Oncol. 2021 Oct 01;43(7):e935-e940. doi: 10.1097/MPH.0000000000002272.

INTRODUCTION: Cytomegalovirus (CMV) infections in developing countries are experienced at an early age. This study was performed to investigate the frequency of reactivation and risk factors of infection acquired at an early age of nontransplant acute lymphoblastic leukemia (ALL)...

Cite
Şen S, Özdemir HH, Karadaş N, et al. Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?. J Pediatr Hematol Oncol. 2021;43(7):e935-e940doi: 10.1097/MPH.0000000000002272.
Şen, S., Özdemir, H. H., Karadaş, N., Bal, Z. �. �., Göktepe, �. �. �. �., Ece, D., Balkan, C., Aydinok, Y., & Karapinar, D. Y. (2021). Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?. Journal of pediatric hematology/oncology, 43(7), e935-e940. https://doi.org/10.1097/MPH.0000000000002272
Şen, Semra, et al. "Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?." Journal of pediatric hematology/oncology vol. 43,7 (2021): e935-e940. doi: https://doi.org/10.1097/MPH.0000000000002272
Şen S, Özdemir HH, Karadaş N, Bal ZŞ, Göktepe ŞÖ, Ece D, Balkan C, Aydinok Y, Karapinar DY. Is Monitoring of Cytomegalovirus Disease Required in Nontransplant Pediatric Acute Lymphoblastic Leukemia?. J Pediatr Hematol Oncol. 2021 Oct 01;43(7):e935-e940. doi: 10.1097/MPH.0000000000002272. PMID: 34387629.
Copy Download .nbib Format: NLM
Juvenile Xanthogranuloma of the Pancreas in a Pediatric Patient Mimicking Pancreatic Neoplasm With High CA 19-9: Case Report and Literature Review.

Journal of pediatric hematology/oncology

Al-Antary E, Gupte A, Poulik J, Klein J, Gorsi HS.
PMID: 34387630
J Pediatr Hematol Oncol. 2021 Aug 16; doi: 10.1097/MPH.0000000000002279. Epub 2021 Aug 16.

Juvenile xanthogranuloma (JXG) is a rare, non-Langerhans cell histiocytosis. It is usually a benign and self-limiting condition. The most common sites are skin and soft tissue. Pancreatic involvement is extremely rare. We present an unusual case of a 13-month-old...

Cite
Al-Antary E, Gupte A, Poulik J, et al. Juvenile Xanthogranuloma of the Pancreas in a Pediatric Patient Mimicking Pancreatic Neoplasm With High CA 19-9: Case Report and Literature Review. J Pediatr Hematol Oncol. 2021;doi: 10.1097/MPH.0000000000002279.
Al-Antary, E., Gupte, A., Poulik, J., Klein, J., & Gorsi, H. S. (2021). Juvenile Xanthogranuloma of the Pancreas in a Pediatric Patient Mimicking Pancreatic Neoplasm With High CA 19-9: Case Report and Literature Review. Journal of pediatric hematology/oncology, . https://doi.org/10.1097/MPH.0000000000002279
Al-Antary, Eman, et al. "Juvenile Xanthogranuloma of the Pancreas in a Pediatric Patient Mimicking Pancreatic Neoplasm With High CA 19-9: Case Report and Literature Review." Journal of pediatric hematology/oncology vol. (2021). doi: https://doi.org/10.1097/MPH.0000000000002279
Al-Antary E, Gupte A, Poulik J, Klein J, Gorsi HS. Juvenile Xanthogranuloma of the Pancreas in a Pediatric Patient Mimicking Pancreatic Neoplasm With High CA 19-9: Case Report and Literature Review. J Pediatr Hematol Oncol. 2021 Aug 16; doi: 10.1097/MPH.0000000000002279. Epub 2021 Aug 16. PMID: 34387630.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 591 entries